Claims:

1. Use of a microbubble-chemotherapeutic agent complex in the manufacture of a medicament for use in combination with a microbubble-sonosensitiser complex in a method of treating cancer via sonodynamic therapy, wherein said sonodynamic therapy comprises simultaneous or sequential use of said microbubble-chemotherapeutic agent complex and said microbubble-sonosensitiser complex, and wherein said chemotherapeutic agent is 5-fluorouracil or gemcitabine and said sonosensitiser is Rose Bengal.

2. Use of a microbubble-chemotherapeutic agent complex which is additionally attached to at least one sonosensitiser in the manufacture of a medicament for use in a method of treating cancer via sonodynamic therapy, wherein said chemotherapeutic agent is 5-fluorouracil or gemcitabine and said sonosensitiser is Rose Bengal.

3. Use as claimed in claim 2, wherein said complex is attached to said at least one sonosensitiser via a non-covalent linkage.

4. Use as claimed in claim 3, wherein said non-covalent linkage is a biotin-avidin interaction.

5. Use as claimed in claim 1, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble attached to at least one chemotherapeutic agent which is 5-fluorouracil or gemcitabine.

6. Use as claimed in claim 5, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble attached to said at least one chemotherapeutic agent via a non-covalent linkage.

7. Use as claimed in claim 6, wherein said non-covalent linkage is a biotin-avidin interaction.

8. Use as claimed in any one of claims 1 to 7, wherein the microbubble-chemotherapeutic agent complex comprises a microbubble having a shell which retains a gas.

9. Use as claimed in claim 8, wherein said gas is oxygen.

10. Use as claimed in any one of claims 1 and 5 to 9, wherein the microbubble-sonosensitiser complex comprises a microbubble having a shell which retains a gas.

11. Use as claimed in claim 10, wherein said gas is oxygen.

12. Use as claimed in any preceding claim, wherein said microbubble-chemotherapeutic agent complex and/or said microbubble-sonosensitiser complex comprises a microbubble having a diameter in the range 0.5 to 100μm.

13. Use as claimed in any preceding claim, wherein said microbubble-chemotherapeutic agent complex and/or said microbubble-sonosensitiser complex comprises a phospholipid monolayer shell having linked thereto one or more polymers.

14. A pharmaceutical composition comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 2 to 4, together with at least one pharmaceutical carrier or excipient.

15. A pharmaceutical composition as claimed in claim 14, wherein said microbubble-chemotherapeutic agent complex comprises a microbubble having non-covalently bound thereto at least one chemotherapeutic agent and at least one sonosensitiser.

16. A pharmaceutical composition comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13, and a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 13, together with at least one pharmaceutical carrier or excipient.

17. Use of a pharmaceutical composition as claimed in any one of claims 14 to 16 in the manufacture of a medicament for use in a method of treating cancer via sonodynamic therapy.

18. Use as claimed in claim 17, wherein said method of treating cancer via sonodynamic therapy comprises simultaneous diagnostic imaging of cancer.

19. Use as claimed in claim 17 or claim 18, wherein said medicament is for use in a method of treating cancer via sonodynamic therapy in which said composition is to be contacted with cells or tissues of a patient and, either simultaneously or sequentially, said cells or tissues are to be subjected to irradiation with ultrasound.

20. Use as claimed in any one of claims 17 to 19, wherein said cancer is selected from the group consisting of sarcomas, including osteogenic and soft tissue sarcomas, carcinomas, lymphomas, including Hodgkin and non-Hodgkin lymphomas, neuroblastoma, melanoma, myeloma, Wilm's tumour, and leukemias, including acute lymphoblastic leukaemia and acute myeloblastic leukaemia, astrocytomas, gliomas and retinoblastomas.

21. Use as claimed in claim 20, wherein said cancer is breast, lung, cerebral, bladder, thyroid, prostate, colon, rectum, pancreas, stomach, liver, uterine, hepatic, renal, prostate, cervical or ovarian carcinoma.

22. Use as claimed in claim 20, wherein said cancer is pancreatic cancer.

23. Use of a product comprising a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13, and a microbubble-

sonosensitiser complex as defined in any one of claims 1 and 10 to 13 in the manufacture of a medicament for simultaneous or sequential use in a method of treating cancer via sonodynamic therapy.

24. A kit comprising the following components: (i) a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13; and separately (ii) a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 13; optionally together with (iii) instructions for the use of said components in a method of treating cancer via sonodynamic therapy.

25. Use of a microbubble-sonosensitiser complex as defined in any one of claims 1 and 10 to 13 in the manufacture of a medicament for use in the treatment of cancer via sonodynamic therapy, wherein said sonodynamic therapy comprises simultaneous or sequential use of a microbubble-chemotherapeutic agent complex as defined in any one of claims 1, 5 to 9, 12 and 13.

26. Use as claimed in claim 1 or claim 25, wherein said medicament is for use in a method of treating cancer via sonodynamic therapy and simultaneous diagnostic imaging of cancer.